<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075894</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000349473</org_study_id>
    <secondary_id>NABTT-0303</secondary_id>
    <nct_id>NCT00075894</nct_id>
  </id_info>
  <brief_title>Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas</brief_title>
  <official_title>A Phase I/II, Open-Label, Non-Randomized, Multicenter, Single Agent Study Of Intravenous SDX-102 For The Treatment Of Patients With MTAP-Deficient High Grade Recurrent Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as alanosine, use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of alanosine in&#xD;
      treating patients with high-grade progressive or recurrent malignant gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of alanosine (SDX-102) with or without&#xD;
           enzyme-inducible antiepileptic drugs (EIAEDs) in patients with methylthioadenosine&#xD;
           phosphorylase (MTAP)-deficient high-grade progressive or recurrent malignant gliomas.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug administered concurrently with EIAEDs in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized, multicenter, dose-escalation study. Patients&#xD;
      are stratified according to concurrent anticonvulsant drug use (drugs that induce hepatic&#xD;
      metabolic enzymes vs drugs that cause modest or no induction of hepatic metabolic enzymes OR&#xD;
      no anticonvulsant drug).&#xD;
&#xD;
      Patients receive alanosine (SDX-102) IV continuously for 5 days. Courses repeat every 21 days&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of SDX-102 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 1 week and then every 2 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-alanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant glioma of 1 of the following types:&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Anaplastic oligodendroglioma&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
          -  Progressive or recurrent disease after prior radiotherapy with or without chemotherapy&#xD;
&#xD;
               -  Low-grade glioma that progressed after prior radiotherapy with or without&#xD;
                  chemotherapy and is found to be high-grade glioma after biopsy allowed&#xD;
&#xD;
               -  No more than 2 prior treatment regimens&#xD;
&#xD;
          -  Measurable disease by CT scan or MRI&#xD;
&#xD;
          -  Documented absence of methylthioadenosine phosphorylase (MTAP) on fixed tumor&#xD;
             specimens&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Transaminases ≤ 4 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception before, during, and for 4&#xD;
             weeks after study participation&#xD;
&#xD;
          -  Mini mental state exam score of ≥ 15&#xD;
&#xD;
          -  No psychological or sociological condition, addictive disorder, or family problem that&#xD;
             would preclude study compliance&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix or breast&#xD;
&#xD;
          -  No concurrent serious infection or medical illness that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic growth factors (e.g., filgrastim [G-CSF] or sargramostim&#xD;
             [GM-CSF])&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Must be maintained on a stable or lower corticosteroid regimen from the time of the&#xD;
             baseline scan until the start of study treatment&#xD;
&#xD;
          -  No concurrent steroids as antiemetics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 months since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 10 days since prior anticonvulsant drugs that induce hepatic metabolic&#xD;
             enzymes&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Surasak Phuphanich, MD, FAAN</last_name>
    <role>Study Chair</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute at University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2004</study_first_posted>
  <last_update_submitted>January 10, 2009</last_update_submitted>
  <last_update_submitted_qc>January 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2009</last_update_posted>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

